NIKKEI 225
39,346.92 +559.54 (+1.44%) HANG SENG
19,641.17 +87.56 (+0.45%) CRUDE OIL
80.02 -0.04 (-0.05%) GOLD FUTURES
2,440.10 +22.70 (+0.94%) DOW
40,003.59 +134.19 (+0.34%) Bitcoin GBP
52,478.68 -392.17 (-0.74%)
ZLAB Sep 2024 30.000 put
| Previous close | 11.10 |
| Open | 11.10 |
| Bid | 14.10 |
| Ask | 17.50 |
| Strike | 30.00 |
| Expiry date | 2024-09-20 |
| Day's range | 11.10 - 11.10 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
GuruFocus.comInsider Sale: Chief Legal Officer of Zai Lab Ltd (ZLAB) Sells Shares
Edmondson Frazor Titus III, Chief Legal Officer of Zai Lab Ltd (NASDAQ:ZLAB), executed a sale of 10,000 shares of the company on May 14, 2024.
Business WireZai Lab Announces Participation in May and June Investor Conferences
SHANGHAI & CAMBRIDGE, Mass., May 16, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in May and June 2024:
Business WireZai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
SHANGHAI & CAMBRIDGE, Mass., May 14, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the supplemental Biologics License Application (sBLA) for efgartigimod alfa injection (subcutaneous injection) (efgartigimod SC) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). The CDE granted priority review on May 11, 2024 and Breakthrough Therapy D
